Associated Papers
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
Genetic Analysis of Neurite Outgrowth Inhibitor-Associated Genes in Parkinson's Disease: A Cross-Sectional Cohort Study.
Huang X et al.
Cns Neuroscience & Therapeutics, 2024
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.
Mondal K et al.
Cells, 2024
Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures.
Alcaniz J et al.
Frontiers in Oncology, 2023
37114125 (PubMed )
Supplement: Table_1.xlsx › Mutations
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.
Cekani E et al.
Cancers, 2022
KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples.
Loong HH et al.
Translational Lung Cancer Research, 2020
Primary malignant melanoma of esophagus: clinicopathologic characterization of 20 cases including molecular genetic profiling of 15 tumors.
Lasota J et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2019
Comprehensive Validation of Snapback Primer-Based Melting Curve Analysis to Detect Nucleotide Variation in the Codon 12 and 13 of KRAS Gene.
Zhang Q et al.
Biomed Research International, 2018
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.
Xu J et al.
The Journal of Clinical Investigation, 2016
Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.
Redig AJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.
Osumi H et al.
Molecular and Clinical Oncology, 2015
Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP et al.
Oncotarget, 2015
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.
Said R et al.
Oncotarget, 2014
Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers.
Spaans VM et al.
Plos One, 2014
Select a paper to view details